NASDAQ:EPRX Eupraxia Pharmaceuticals 3/20/2025 Earnings Report $5.29 -0.12 (-2.22%) Closing price 03:50 PM EasternExtended Trading$5.34 +0.05 (+0.95%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Eupraxia Pharmaceuticals EPS ResultsActual EPS-$0.21Consensus EPS -$0.20Beat/MissMissed by -$0.01One Year Ago EPSN/AEupraxia Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEupraxia Pharmaceuticals Announcement DetailsQuarterDate3/20/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsEupraxia Pharmaceuticals' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Eupraxia Pharmaceuticals Earnings HeadlinesEupraxia Pharmaceuticals (EPRX) Receives a Buy from Raymond JamesJuly 11, 2025 | theglobeandmail.comEupraxia Pharma Shares Climb on Dosing of First EP-104GI Study PatientJuly 8, 2025 | marketwatch.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 18 at 2:00 AM | Porter & Company (Ad)Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic EsophagitisJuly 8, 2025 | globenewswire.comEupraxia Pharmaceuticals Stock Short Interest Report | NASDAQ:EPRX - BenzingaJune 27, 2025 | benzinga.comEupraxia Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:EPRX - BenzingaJune 26, 2025 | benzinga.comSee More Eupraxia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email. Email Address About Eupraxia PharmaceuticalsEupraxia Pharmaceuticals (NASDAQ:EPRX), Inc. is a clinical-stage biotechnology company focused on developing engineered bacterial therapies for gastrointestinal and liver diseases. The company’s proprietary platform leverages synthetic biology to engineer nonpathogenic microbial strains capable of producing therapeutic molecules directly at sites of disease within the gut. By combining microbiome science with precision genetic engineering, Eupraxia aims to address conditions that have proven difficult to treat with conventional small molecules or biologics. The company’s pipeline comprises multiple lead programs in early clinical and preclinical development. These candidates are designed to modulate immune and metabolic pathways through localized delivery of bioactive proteins and peptides. Eupraxia’s approach seeks to reduce systemic exposure and off-target effects by confining therapeutic activity to the gastrointestinal tract. Key areas of investigation include inflammatory bowel diseases, cholestatic liver disorders and other chronic GI conditions with high unmet medical need. Headquartered in Dallas, Texas, Eupraxia Pharmaceuticals went public on the Nasdaq Global Market under the ticker symbol EPRX. The company is led by a team of experienced biopharmaceutical executives and scientists with expertise in synthetic biology, microbiome research and clinical development. Through strategic partnerships and a growing pipeline, Eupraxia aims to advance novel microbial therapies that could transform the treatment landscape for digestive and liver diseases.Written by Jeffrey Neal JohnsonView Eupraxia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
